Transition from metabolic adaptation to maladaptation of the heart in obesity: Role of apelin

International Journal of Obesity

Volumn 39, Issue 2, 2015, Pages 312-320

  Alfarano, C ^a,b   Foussal, C ^a,b   Lairez, O ^a   Calise, D ^b,c   Attane C ^a,b   Anesia, R ^a,b   Daviaud, D ^a,b   Wanecq, E ^a,b   Parini, A ^a,b   Valet, P ^a,b   Kunduzova, O ^a,b  

^a CHU RANGUEIL   (France)

^b University Hospital of Toulouse   (France)

^c Microsurgery Services   (France)

Author keywords

[No Author keywords available]

Indexed keywords

APELIN; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CELL NUCLEUS DNA; CITRATE SYNTHASE; GLUCOSE; INSULIN; MITOCHONDRIAL DNA; MITOCHONDRIAL TRANSCRIPTION FACTOR A; NUCLEAR RESPIRATORY FACTOR 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; SIRTUIN 3; ADIPOCYTOKINE; APLN PROTEIN, MOUSE; SIGNAL PEPTIDE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY FAT; BODY WEIGHT; DNA DETERMINATION; DOWN REGULATION; ECHOCARDIOGRAPHY; ELECTRON MICROSCOPY; ENZYME ACTIVITY; FAT MASS; FATTY ACID METABOLISM; FATTY ACID OXIDATION; GENETIC TRANSFECTION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE OXIDATION; GLUCOSE TOLERANCE; GLUCOSE TOLERANCE TEST; HEART EJECTION FRACTION; HEART FAILURE; HEART FUNCTION; HEART HYPERTROPHY; HEART MUSCLE CELL; HEART MUSCLE METABOLISM; HEART VENTRICLE HYPERTROPHY; IMMUNOBLOTTING; IMPAIRED GLUCOSE TOLERANCE; IN VIVO STUDY; INSULIN BLOOD LEVEL; LIPID DIET; MALE; MOUSE; NONHUMAN; OBESITY; PRIMARY CULTURE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CARDIAC MUSCLE; CARDIAC MUSCLE CELL; DISEASE MODEL; METABOLISM; OXIDATION REDUCTION REACTION; PATHOLOGY;

MUS;

ADIPOKINES; ANIMALS; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; HEART FAILURE; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICE; MICE, INBRED C57BL; MYOCARDIUM; MYOCYTES, CARDIAC; OBESITY; OXIDATION-REDUCTION;

EID: 84922628200     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2014.122     Document Type: Article

References (38)

1. Taegtmeyer H. Energy metabolism of the heart: from basic concepts to clinical applications. Curr Probl Cardiol 1994; 19: 59-113.
2. Lopaschuk GD, Belke DD, Gamble J, Itoi T, Schonekess BO. Regulation of fatty acid oxidation in the mammalian heart in health and disease. Biochim Biophys Acta 1994; 1213: 263-276.
3. Van der Vusse GJ, van Bilsen M, Glatz JF. Cardiac fatty acid uptake and transport in health and disease. Cardiovasc Res 2000; 45: 279-293.
4. Visser FC. Imaging of cardiac metabolism using radiolabelled glucose, fatty acids and acetate. Coron Artery Dis 2001; 12 (Suppl 1): S12-S18.
5. Hendrickson SC St, Louis JD, Lowe JE, Abdel-aleem S. Free fatty acid metabolism during myocardial ischemia and reperfusion. Mol Cell Biochem 1997; 166: 85-94.
6. Katz AM. Metabolism of the failing heart. Cardioscience 1993; 4: 199-203.
7. Lopaschuk GD, Stanley WC. Glucose metabolism in the ischemic heart. Circulation 1997; 95: 313-315.
8. Tian R, Abel ED. Responses of GLUT4-deficient hearts to ischemia underscore the importance of glycolysis. Circulation 2001; 103: 2961-2966.
9. Essop MF, Opie LH. Metabolic therapy for heart failure. Eur Heart J 2004; 25: 1765-1768.
10. Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS, Stanley WC. Myocardial fatty acid metabolism in health and disease. Physiol Rev 2010; 90: 207-258.
11. Stanley WC, Lopaschuk GD, Hall JL, McCormack JG. Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Potential for pharmacological interventions. Cardiovasc Res 1997; 33: 243-257.
12. Abel ED, Litwin SE, Sweeney G. Cardiac remodeling in obesity. Physiol Rev 2008; 88: 389-419.
13. Romacho T, Elsen M, Röhrborn D, Eckel J. Adipose tissue and its role in organ crosstalk. Acta Physiol 2014; 210: 733-753.
14. Nakamura K, Fuster JJ, Walsh K. Adipokines: a link between obesity and cardiovascular disease. J Cardiol 2014; 63: 250-259.
15. Blüher M. Adipose tissue dysfunction contributes to obesity related metabolic diseases. Best Pract Res Clin Endocrinol Metab 2013; 27: 163-177.
16. Kleinz MJ, Davenport AP. Emerging roles of apelin in biology and medicine. Pharmacol Ther 2005; 107: 198-211.
17. Foussal C, Lairez O, Calise D, Pathak A, Guilbeau-Frugier C, Valet P et al. Activation of catalase by apelin prevents oxidative stress-linked cardiac hypertrophy. FEBS Lett 2010; 584: 2363-2370.
18. Kuba K, Zhang L, Imai Y, Arab S, Chen M, Maekawa Y et al. Impaired heart contractility in apelin gene-deficient mice associated with aging and pressure overload. Circ Res 2007; 101: e32-e42.
19. Boucher J, Masri B, Daviaud D, Gesta S, Guigne C, Mazzucotelli A et al. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology 2005; 146: 1764-1771.
20. Dray C, Knauf C, Daviaud D, Waget A, Boucher J, Buleon M et al. Apelin stimulates glucose utilization in normal and obese insulin-resistant mice. Cell Metab 2008; 8: 437-445.
21. Attane C, Foussal C, Le Gonidec S, Benani A, Daviaud D, Wanecq E et al. Apelin treatment increases complete Fatty Acid oxidation, mitochondrial oxidative capacity, and biogenesis in muscle of insulin-resistant mice. Diabetes 2012; 61: 310-320.
22. Zeng H, He X, Hou X, Li L, Chen JX. Apelin gene therapy increases myocardial vascular density and ameliorates diabetic cardiomyopathy via upregulation of sirtuin 3. Am J Physiol Heart Circ Physiol 2014; 306: H585-H597.
23. Sinatra ST. Metabolic cardiology: an integrative strategy in the treatment of congestive heart failure. Altern Ther Health Med 2009; 15: 44-52.
24. Tian R, Abel ED. Responses of GLUT4-deficient hearts to ischemia underscore the importance of glycolysis. Circulation 2001; 103: 2961-2966.
25. Yan J, Young ME, Cui L, Lopaschuk GD, Liao R, Tian R. Increased glucose uptake and oxidation in mouse hearts prevent high fatty acid oxidation but cause cardiac dysfunction in diet-induced obesity. Circulation 2009; 119: 2818-2828.
26. Nagoshi T, Yoshimura M, Rosano GM, Lopaschuk GD, Mochizuki S. Optimization of cardiac metabolism in heart failure. Curr Pharm Des 2011; 17: 3846-3853.
27. Allard MF, Emanuel PG, Russell JA, Bishop SP, Digerness SB, Anderson PG. Preischemic glycogen reduction or glycolytic inhibition improves postischemic recovery of hypertrophied rat hearts. Am J Physiol 1994; 267: H66-H74.
28. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol. Rev. 2005; 85: 1093-1129.
29. Augustus AS, Buchanan J, Park TS, Hirata K, Noh HL, Sun J et al. Loss of lipoprotein lipase-derived fatty acids leads to increased cardiac glucose metabolism and heart dysfunction. J Biol Chem 2006; 281: 8716-8723.
30. Iwanaga Y, Kihara Y, Takenaka H, Kita T. Down-regulation of cardiac apelin system in hypertrophied and failing hearts: Possible role of angiotensin II-angiotensin type 1 receptor system. J Mol Cell Cardiol 2006; 41: 798-806.
31. Koguchi W, Kobayashi N, Takeshima H, Ishikawa M, Sugiyama F, Ishimitsu T. Cardioprotective effect of apelin-13 on cardiac performance and remodeling in end-stage heart failure. Circ J 2012; 76: 137-144.
32. Japp AG, Cruden NL, Barnes G, van Gemeren N, Mathews J, Adamson J et al. Acute cardiovascular effects of apelin in humans:Potential role in patients with chronic heart failure. Circulation 2010; 121: 1818-1827.
33. Scimia MC, Hurtado C, Ray S, Metzler S, Wei K, Wang J et al. APJ acts as a dual receptor in cardiac hypertrophy. Nature 2012; 488: 394-398.
34. Rosca MG, Vazquez EJ, Kerner J, Parland W, Chandler MP, Stanley W et al. Cardiac mitochondria in heart failure: decrease in respirasomes and oxidative phosphorylation. Cardiovasc Res 2008; 80: 30-39.
35. Sharov VG, Todor AV, Silverman N, Goldstein S, Sabbah HN. Abnormal mitochondrial respiration in failed human myocardium. J Mol Cell Cardiol 2000; 32: 2361-2367.
36. Frier BC, Williams DB, Wright DC. The effects of apelin treatment on skeletal muscle mitochondrial content. Am J Physiol Regul Integr Comp Physiol 2009; 297: R1761-R1768.
37. Schwer B, North BJ, Frye RA, Ott M, Verdin E. The human silent information regulator (Sir)2 homologue hSIRT3 is a mitochondrial nicotinamide adenine dinucleotide-dependent deacetylase. J Cell Biol 2002; 158: 647-657.
38. Ahn BH, Kim HS, Song S, Lee IH, Liu J, Vassilopoulos A, Deng CX, Finkel T. A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis. Proc Natl Acad Sci USA 2008; 105: 14447-14452.